<DOC>
	<DOC>NCT02196636</DOC>
	<brief_summary>This two-part study will assess the safety and tolerability of single ascending oral doses of RO6806127 in a group of healthy male participants and investigate the effect of high fat and high caloric food on the relative bioavailability of a single oral dose of RO6806127 in a separate group of healthy male participants. The relationship between drug exposure and tolerability will be explored.</brief_summary>
	<brief_title>A Phase 1 Study of RO6806127 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male participants aged 18 to 45 years, inclusive A BMI between 18 to 30 kg/m2, inclusive Agreement to use highly effective contraception Clinically significant abnormalities in laboratory test results History of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis Significant disorders of the central nervous system, including psychiatric disorders, behavioral disturbances, cerebrovascular events, depression, bipolar disorder, migraine, Parkinson, anxiety, any personal or familial history of seizures, epilepsy or other convulsive condition, previous significant head trauma, or other factors predisposing to seizures Use of any prohibited medications and food before study start and during the study Dietary restrictions that would prohibit the consumption of standardized meals</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>